Tags: hemophilia | eloctate | clotting | drug

Hemophilia Treatment Requires Fewer Injections

Thursday, 26 Jun 2014 05:18 PM

Eloctate, Antihemophilic Factor Fc Fusion has been approved by the U.S. Food and Drug Administration for people with Hemophilia A.

It's designed to require less frequent injections than standard therapies used to reduce the frequency of bleeding episodes in people with the disorder, the FDA said in a news release.
Hemophilia A is an inherited bleeding disorder that affects mostly males. Caused by a defective Factor VIII gene, it affects about 1 in 5,000 males in the United States. People with the disorder are prone to serious bleeding episodes, primarily affecting the joints.

Eloctate's safety and effectiveness were evaluated in a clinical study of 164 people. No safety concerns were identified in the trial, the FDA said.

The product is produced by Biogen Idec, based in Cambridge, Mass.

© HealthDay

 
1Like our page
2Share
FDA-Approved-Drugs
Eloctate, Antihemophilic Factor Fc Fusion has been approved by the U.S. Food and Drug Administration for people with Hemophilia A. It's designed to require less frequent injections than standard therapies used to reduce the frequency of bleeding episodes in people with...
hemophilia, eloctate, clotting, drug
128
2014-18-26
Thursday, 26 Jun 2014 05:18 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved